Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

oludare

  • Home
  •  
  • oludare



  • Most Read
  • Latest Comments
  • Zelira enrols sixty patients for diabetic nerve pain drug trial as it attempts to overthrow major pharma company
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Zelira enrols sixty patients for diabetic nerve pain drug trial as it attempts to overthrow major pharma company
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Zelira enrols sixty patients for diabetic nerve pain drug trial as it attempts to overthrow major pharma company
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Zelira enrols sixty patients for diabetic nerve pain drug trial as it attempts to overthrow major pharma company
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Zelira enrols sixty patients for diabetic nerve pain drug trial as it attempts to overthrow major pharma company
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    • News

  • Zelira enrols sixty patients for diabetic nerve pain drug trial as it attempts to overthrow major pharma company
    Zelira enrols sixty patients for diabetic nerve pain drug trial as it attempts to overthrow major pharma company
    • News

  • Cannabis toothpaste is a thing, and Zelira Therapeutics are commercialising it
    Cannabis toothpaste is a thing, and Zelira Therapeutics are commercialising it
    • News

  • Zelda to launch clinical trials testing cannabis as solution to insomnia
    Zelda to launch clinical trials testing cannabis as solution to insomnia
    • News

  • Zelira enrols sixty patients for diabetic nerve pain drug trial as it attempts to overthrow major pharma company
    • News

    Zelira enrols sixty patients for diabetic nerve pain drug trial as it attempts to overthrow major pharma company

    Biopharmaceuticals company Zelira (ASX: ZLD) is taking a stab at redemption. After a misstep this July by not announcing its German expansion, the Company lost shareholder trust. Now, it is attempting to get it back with new milestones revealed on time for its clinical trials targeting diabetic nerve pain.  The trial has been designed as

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.